Fungal Necrotizing Skin and Soft Tissue Infections

  • Logan Bartram
  • Justin G. AaronEmail author
Fungal Infections of Skin and Subcutaneous Tissue (A Bonifaz and M Pereira, Section Editors)
Part of the following topical collections:
  1. Topical Collection on Fungal Infections of Skin and Subcutaneous Tissue


Purpose of Review

This review summarizes the medical literature regarding fungal necrotizing skin and soft tissue infections (NSTI). The available epidemiologic, microbiologic, treatment, and outcome data are presented by the most common causal organisms of this disease process.

Recent Findings

With the exception of cutaneous mucormycosis, which often progresses to necrotizing infection, clinical data for other fungal NSTI are largely limited to case reports and small case series. Fungal NSTI are rare but some data suggests that incidence may be increasing. These infections occur in both immunocompromised and immunocompetent hosts, especially following trauma. Mortality varies by host factors, organism, and extent of disease. Foundations of treatment include targeted antifungal therapy and aggressive surgical debridement.


Fungal NSTI is a rarely described clinical entity associated with a high mortality. More study is needed to better understand the epidemiology and optimal management of these infections.


Fungal Necrotizing skin and soft tissue infection Necrotizing soft tissue infection Necrotizing fasciitis Mucormycosis NSTI 


Compliance with Ethical Standards

Conflict of Interest

Logan Bartram and Justin Aaron declare no conflicts of interest relevant to this manuscript.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.


Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. 1.
    • Stevens DL, Bryant AE. Necrotizing Soft-Tissue Infections. New England Journal of Medicine. 2017;377(23):2253–65. general review of bacterial necrotizing soft tissue infections with a focus on epidemiology, diagnostic and treatment strategies.CrossRefPubMedGoogle Scholar
  2. 2.
    Bonne SL, Kadri SS. Evaluation and Management of Necrotizing Soft Tissue Infections. Infect Dis Clin North Am. 2017;31(3):497–511. Scholar
  3. 3.
    Khamnuan P, Chongruksut W, Jearwattanakanok K, Patumanond J, Yodluangfun S, Tantraworasin A. Necrotizing fasciitis: risk factors of mortality. Risk Manag Healthc Policy. 2015;8:1–7. Scholar
  4. 4.
    Naseer U, Steinbakk M, Blystad H, Caugant DA. Epidemiology of invasive group A streptococcal infections in Norway 2010-2014: A retrospective cohort study. Eur J Clin Microbiol Infect Dis. 2016;35(10):1639–48. Scholar
  5. 5.
    Glass GE, Sheil F, Ruston JC, Butler PE. Necrotising soft tissue infection in a UK metropolitan population. Ann R Coll Surg Engl. 2015;97(1):46–51. Scholar
  6. 6.
    Bocking N, Matsumoto CL, Loewen K, Teatero S, Marchand-Austin A, Gordon J, et al. High Incidence of Invasive Group A Streptococcal Infections in Remote Indigenous Communities in Northwestern Ontario, Canada. Open Forum Infect Dis. 2017;4(1):ofw243. Scholar
  7. 7.
    Anaya DA, Dellinger EP. Necrotizing soft-tissue infection: diagnosis and management. Clin Infect Dis. 2007;44(5):705–10. Scholar
  8. 8.
    McHenry CR, Piotrowski JJ, Petrinic D, Malangoni MA. Determinants of mortality for necrotizing soft-tissue infections. Ann Surg. 1995;221(5):558–63; discussion 63-5. Scholar
  9. 9.
    Willis RN, Guidry CA, Horn CB, Gilsdorf D, Davies SW, Dietch ZC, et al. Predictors of Monomicrobial Necrotizing Soft Tissue Infections. Surg Infect (Larchmt). 2015;16(5):533–7. Scholar
  10. 10.
    Singh G, Ray P, Sinha SK, Adhikary S, Khanna SK. Bacteriology of Necrotizing Infections of Soft Tissues. Australian and New Zealand Journal of Surgery. 1996;66(11):747–50. Scholar
  11. 11.
    Moore SA, Levy BH, Prematilake C, Dissanaike S. The Prediction Predicament: Rethinking Necrotizing Soft Tissue Infections Mortality. Surg Infect (Larchmt). 2015;16(6):813–21. Scholar
  12. 12.
    •• Horn CB, Wesp BM, Fiore NB, Rasane RK, Torres HA, Turnbull IR, et al. Fungal Infections Increase the Mortality Rate Three-Fold in Necrotizing Soft-Tissue Infections. Surgical Infections. 2017;18(7):793–8. largest retrospective case series specifically designed to estimate the rates of fungal involvement within necrotizing soft tissue infections as isolated from initial intraoperative cultures. CrossRefPubMedGoogle Scholar
  13. 13.
    •• Roden MM, Zaoutis TE, Buchanan WL, Knudsen TA, Sarkisova TA, Schaufele RL, et al. Epidemiology and outcome of zygomycosis: a review of 929 reported cases. Clin Infect Dis. 2005;41(5):634–53. first large-scale systematic review of mucormycosis which serves as a baseline specifically detailing the epidemiology and outcomes of this disease between 1940 and 2003. CrossRefPubMedGoogle Scholar
  14. 14.
    Bitar D, Van Cauteren D, Lanternier F, Dannaoui E, Che D, Dromer F, et al. Increasing incidence of zygomycosis (mucormycosis), France, 1997-2006. Emerg Infect Dis. 2009;15(9):1395–401. Scholar
  15. 15.
    Neofytos D, Horn D, Anaissie E, Steinbach W, Olyaei A, Fishman J, et al. Epidemiology and outcome of invasive fungal infection in adult hematopoietic stem cell transplant recipients: analysis of Multicenter Prospective Antifungal Therapy (PATH) Alliance registry. Clin Infect Dis. 2009;48(3):265–73. Scholar
  16. 16.
    • Rammaert B, Lanternier F, Zahar JR, Dannaoui E, Bougnoux ME, Lecuit M, et al. Healthcare-associated mucormycosis. Clin Infect Dis. 2012;54 Suppl 1:S44–54. review of mucormycosis within healthcare settings also detailing case clusters and outbreaks with a notably large proportion of cutaneous disease. CrossRefPubMedGoogle Scholar
  17. 17.
    Skiada A, Rigopoulos D, Larios G, Petrikkos G, Katsambas A. Global epidemiology of cutaneous zygomycosis. Clin Dermatol. 2012;30(6):628–32. Scholar
  18. 18.
    •• Jeong W, Keighley C, Wolfe R, Lee WL, Slavin MA, Kong DCM, et al. The epidemiology and clinical manifestations of mucormycosis: a systematic review and meta-analysis of case reports. Clin Microbiol Infect. 2019;25(1):26–34. recent systematic review of 851 cases of mucormycosis reported between 2000 and 2017 with the aim to update understanding of the epidemiology, associated underlying comorbidities, microbiology and outcomes of this disease process. CrossRefPubMedGoogle Scholar
  19. 19.
    Giuliano A, Lewis F Jr, Hadley K, Blaisdell FW. Bacteriology of necrotizing fasciitis. Am J Surg. 1977;134(1):52–7. Scholar
  20. 20.
    Morgan MS. Diagnosis and management of necrotising fasciitis: a multiparametric approach. J Hosp Infect. 2010;75(4):249–57. Scholar
  21. 21.
    Wong CH, Chang HC, Pasupathy S, Khin LW, Tan JL, Low CO. Necrotizing fasciitis: clinical presentation, microbiology, and determinants of mortality. J Bone Joint Surg Am. 2003;85(8):1454–60.CrossRefGoogle Scholar
  22. 22.
    • Warkentien T, Rodriguez C, Lloyd B, Wells J, Weintrob A, Dunne JR, et al. Invasive mold infections following combat-related injuries. Clin Infect Dis. 2012;55(11):1441–9. case series of post-traumatic, combat associated necrotizing soft tissue infections due to invasive molds. CrossRefPubMedPubMedCentralGoogle Scholar
  23. 23.
    • Pappas PG, Kauffman CA, Andes DR, Clancy CJ, Marr KA, Ostrosky-Zeichner L, et al. Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America. Clin Infect Dis. 2016;62(4):e1–50. most recent IDSA practice guidelines for the treatment of Candidiasis in general with treatment implications for patients with invasive cutaneous disease. CrossRefPubMedGoogle Scholar
  24. 24.
    Buchanan PJ, Mast BA, Lottenberg L, Kim T, Efron PA, Ang DN. Candida albicans necrotizing soft tissue infection: a case report and literature review of fungal necrotizing soft tissue infections. Ann Plast Surg. 2013;70(6):739–41. Scholar
  25. 25.
    Johnin K, Nakatoh M, Kadowaki T, Kushima M, Koizumi S, Okada Y. Fournier's gangrene caused by Candida species as the primary organism. Urology. 2000;56(1):153. Scholar
  26. 26.
    Perkins TA, Bieniek JM, Sumfest JM. Solitary Candida albicans Infection Causing Fournier Gangrene and Review of Fungal Etiologies. Rev Urol. 2014;16(2):95–8.PubMedPubMedCentralGoogle Scholar
  27. 27.
    Eisen DB, Brown E. Necrotizing fasciitis following a motor vehicle accident with Candida species as the sole organisms. Can J Plast Surg. 2004;12(1):43–6. Scholar
  28. 28.
    Jordan A, Sharma P, Moss C, Durrani A, Price R. Cervico-facial necrotising fasciitis due to Candida albicans. European Journal of Plastic Surgery. 2013;36(7):453–6. Scholar
  29. 29.
    Loulergue P, Mahe V, Bougnoux ME, Poiree S, Hot A, Lortholary O. Fournier's gangrene due to Candida glabrata. Med Mycol. 2008;46(2):171–3. Scholar
  30. 30.
    Gassiep I, Douglas J, Playford EG. First report of monomicrobial Candida parapsilosis necrotizing fasciitis. Transpl Infect Dis. 2016;18(5):752–5. Scholar
  31. 31.
    Baer S, Baddley JW, Gnann JW, Pappas PG. Cryptococcal disease presenting as necrotizing cellulitis in transplant recipients. Transpl Infect Dis. 2009;11(4):353–8. Scholar
  32. 32.
    Chayakulkeeree M, Perfect JR. Cryptococcosis. Infect Dis Clin North Am. 2006;20(3):507–44, v-vi. Scholar
  33. 33.
    Molina-Leyva A, Ruiz-Carrascosa JC, Leyva-Garcia A, Husein-Elahmed H. Cutaneous Cryptococcus laurentii infection in an immunocompetent child. Int J Infect Dis. 2013;17(12):e1232–3. Scholar
  34. 34.
    Narayan S, Batta K, Colloby P, Tan CY. Cutaneous cryptococcus infection due to C. albidus associated with Sezary syndrome. Br J Dermatol. 2000;143(3):632–4. Scholar
  35. 35.
    Hoang JK, Burruss J. Localized cutaneous Cryptococcus albidus infection in a 14-year-old boy on etanercept therapy. Pediatr Dermatol. 2007;24(3):285–8. Scholar
  36. 36.
    • Ho SW, Ang CL, Ding CS, Barkham T, Teoh LC. Necrotizing Fasciitis Caused by Cryptococcus gattii. Am J Orthop (Belle Mead NJ). 2015;44(12):E517–22 A case report of Cryptococcal necrotizing soft tissue infection and review of the literature largely inclusive of cases described to date. Google Scholar
  37. 37.
    Marcus JR, Hussong JW, Gonzalez C, Dumanian GA. Risk factors in necrotizing fasciitis: a case involving Cryptococcus neoformans. Ann Plast Surg. 1998;40(1):80–3.CrossRefGoogle Scholar
  38. 38.
    Richardson TE, Lee NE, Cykowski MD, Chang SA, Powell SZ. Necrotizing fasciitis as the initial presentation of disseminated infection with fluconazole-resistant Cryptococcus neoformans. JMM Case Rep. 2014;1(4):e003608-e. Scholar
  39. 39.
    Capoor MR, Khanna G, Malhotra R, Verma S, Nair D, Deb M, et al. Disseminated cryptococcosis with necrotizing fasciitis in an apparently immunocompetent host: a case report. Med Mycol. 2008;46(3):269–73. Scholar
  40. 40.
    Adachi M, Tsuruta D, Imanishi H, Ishii M, Kobayashi H. Necrotizing fasciitis caused by Cryptococcus neoformans in a patient with pemphigus vegetans. Clin Exp Dermatol. 2009;34(8):e751–3. Scholar
  41. 41.
    Basaran O, Emiroglu R, Arikan U, Karakayali H, Haberal M. Cryptococcal necrotizing fasciitis with multiple sites of involvement in the lower extremities. Dermatol Surg. 2003;29(11):1158–60. Scholar
  42. 42.
    Gave AA, Torres R, Kaplan L. Cryptococcal myositis and vasculitis: an unusual necrotizing soft tissue infection. Surg Infect (Larchmt). 2004;5(3):309–13. Scholar
  43. 43.
    Yoneda T, Itami Y, Hirayama A, Saka T, Yoshida K, Fujimoto K. Cryptococcal necrotizing fasciitis in a patient after renal transplantation--a case report. Transplant Proc. 2014;46(2):620–2. Scholar
  44. 44.
    Begon E, Bachmeyer C, Thibault M, Boulet E, Staub G, Trouillet G, et al. Necrotizing fasciitis due to Cryptococcus neoformans in a diabetic patient with chronic renal insufficiency. Clin Exp Dermatol. 2009;34(8):935–6. Scholar
  45. 45.
    Doorenbos-Bot AC, Hooymans JM, Blanksma LJ. Periorbital necrotising fasciitis due to Cryptococcus neoformans in a healthy young man. Doc Ophthalmol. 1990;75(3-4):315–20. Scholar
  46. 46.
    Hoshino T, Omura K, Kimura S, Takahashi H, Kamei K, Ohkusu M. A case of disseminated cryptococcosis with necrotizing fasciitis in a non-HIV patient. Acute Med Surg. 2017;4(4):454–7. Scholar
  47. 47.
    Van Grieken SA, Dupont LJ, Van Raemdonck DE, Van Bleyenbergh P, Verleden GM. Primary cryptococcal cellulitis in a lung transplant recipient. J Heart Lung Transplant. 2007;26(3):285–9. Scholar
  48. 48.
    Huang KC, Tu YK, Lee KF, Huang TJ, Wen-Wei HR. Disseminated cryptococcosis presented as necrotizing fasciitis of a limb. J Trauma. 2007;63(2):E44–6. Scholar
  49. 49.
    Spellberg B, Edwards J, Ibrahim A. Novel Perspectives on Mucormycosis: Pathophysiology, Presentation, and Management. Clinical Microbiology Reviews. 2005;18(3):556–69. Scholar
  50. 50.
    • Ibrahim AS, Spellberg B, Walsh TJ, Kontoyiannis DP. Pathogenesis of Mucormycosis. Clinical Infectious Diseases. 2012;54(suppl_1):S16–22. review of mucormycosis with particular attention to the pathophysiology of this disease process and implications for novel approaches to therapy. CrossRefPubMedPubMedCentralGoogle Scholar
  51. 51.
    Lanternier F, Dannaoui E, Morizot G, Elie C, Garcia-Hermoso D, Huerre M, et al. A global analysis of mucormycosis in France: the RetroZygo Study (2005-2007). Clin Infect Dis. 2012;54(Suppl 1):S35–43. Scholar
  52. 52.
    • Lelievre L, Garcia-Hermoso D, Abdoul H, Hivelin M, Chouaki T, Toubas D, et al. Posttraumatic mucormycosis: a nationwide study in France and review of the literature. Medicine (Baltimore). 2014;93(24):395–404. analysis of post-traumatic, cutaneous mucormycosis from the RetroZygo study as well as a review of the literature regarding subsequently described cases. CrossRefGoogle Scholar
  53. 53.
    Skiada A, Petrikkos G. Cutaneous zygomycosis. Clinical Microbiology and Infection. 2009;15:41–5. Scholar
  54. 54.
    Kontoyiannis DP, Wessel VC, Bodey GP, Rolston KV. Zygomycosis in the 1990s in a tertiary-care cancer center. Clin Infect Dis. 2000;30(6):851–6. Scholar
  55. 55.
    Maertens J, Demuynck H, Verbeken EK, Zachee P, Verhoef GE, Vandenberghe P, et al. Mucormycosis in allogeneic bone marrow transplant recipients: report of five cases and review of the role of iron overload in the pathogenesis. Bone Marrow Transplant. 1999;24(3):307–12. Scholar
  56. 56.
    Boelaert JR, Van Cutsem J, de Locht M, Schneider YJ, Crichton RR. Deferoxamine augments growth and pathogenicity of Rhizopus, while hydroxypyridinone chelators have no effect. Kidney Int. 1994;45(3):667–71. Scholar
  57. 57.
    de Locht M, Boelaert JR, Schneider YJ. Iron uptake from ferrioxamine and from ferrirhizoferrin by germinating spores of Rhizopus microsporus. Biochem Pharmacol. 1994;47(10):1843–50. Scholar
  58. 58.
    Boelaert JR, Fenves AZ, Coburn JW. Deferoxamine therapy and mucormycosis in dialysis patients: report of an international registry. Am J Kidney Dis. 1991;18(6):660–7.CrossRefGoogle Scholar
  59. 59.
    Kontoyiannis DP, Lionakis MS, Lewis RE, Chamilos G, Healy M, Perego C, et al. Zygomycosis in a tertiary-care cancer center in the era of Aspergillus-active antifungal therapy: a case-control observational study of 27 recent cases. J Infect Dis. 2005;191(8):1350–60. Scholar
  60. 60.
    Skiada A, Pagano L, Groll A, Zimmerli S, Dupont B, Lagrou K, et al. Zygomycosis in Europe: analysis of 230 cases accrued by the registry of the European Confederation of Medical Mycology (ECMM) Working Group on Zygomycosis between 2005 and 2007. Clin Microbiol Infect. 2011;17(12):1859–67. Scholar
  61. 61.
    Neblett Fanfair R, Benedict K, Bos J, Bennett SD, Lo YC, Adebanjo T, et al. Necrotizing cutaneous mucormycosis after a tornado in Joplin, Missouri, in 2011. N Engl J Med. 2012;367(23):2214–25. Scholar
  62. 62.
    Chamilos G, Lewis RE, Kontoyiannis DP. Delaying amphotericin B-based frontline therapy significantly increases mortality among patients with hematologic malignancy who have zygomycosis. Clin Infect Dis. 2008;47(4):503–9. Scholar
  63. 63.
    • Patterson TF, Thompson GR III, Denning DW, Fishman JA, Hadley S, Herbrecht R, et al. Practice Guidelines for the Diagnosis and Management of Aspergillosis: 2016 Update by the Infectious Diseases Society of America. Clin Infect Dis. 2016;63(4):e1–e60. most recent IDSA practice guidelines for the treatment of invasive Aspergillosis with treatment receommendations for patients with cutaneous disease in general. CrossRefPubMedPubMedCentralGoogle Scholar
  64. 64.
    Marr KA, Carter RA, Crippa F, Wald A, Corey L. Epidemiology and outcome of mould infections in hematopoietic stem cell transplant recipients. Clin Infect Dis. 2002;34(7):909–17. Scholar
  65. 65.
    van Burik JA, Colven R, Spach DH. Cutaneous aspergillosis. J Clin Microbiol. 1998;36(11):3115–21. Scholar
  66. 66.
    Falsey AR, Goldsticker RD, Ahern MJ. Fatal subcutaneous aspergillosis following necrotizing fasciitis: a case report. Yale J Biol Med. 1990;63(1):9–13. Scholar
  67. 67.
    Rieder J, Lechner M, Lass-Floerl C, Rieger M, Lorenz I, Piza H, et al. Successful management of Aspergillus liver abscess in a patient with necrotizing fasciitis. Dig Dis Sci. 2007;52(6):1548–53. Scholar
  68. 68.
    Yuen JC, Puri SK, Feng Z. Scalp necrotizing fasciitis with osteomyelitis of the skull from Aspergillus. J Craniofac Surg. 2002;13(6):762–4. Scholar
  69. 69.
    Johnson MA, Lyle G, Hanly M, Yeh KA. Aspergillus: a rare primary organism in soft-tissue infections. Am Surg. 1998;64(2):122–6.PubMedGoogle Scholar
  70. 70.
    Mathew M, Priya P, Mathew S. Scrotal Aspergillosis Associated with Fournier’s Gangrene in a Patient with Cirrhosis. Iranian Journal of Pathology. 2012;7(1):53–7.Google Scholar
  71. 71.
    Rath S, Kar S, Sahu SK, Sharma S. Fungal periorbital necrotizing fasciitis in an immunocompetent adult. Ophthalmic Plast Reconstr Surg. 2009;25(4):334–5. Scholar
  72. 72.
    Abdul Kadir N, Ahmad SS, Abdul Ghani S, Paramananda M. A case of acute periorbital necrotizing fasciitis. Journal of Acute Disease. 2016;5(2):174–6. Scholar
  73. 73.
    Voloshin DK, Lacomis D, McMahon D. Disseminated histoplasmosis presenting as myositis and fasciitis in a patient with dermatomyositis. Muscle Nerve. 1995;18(5):531–5. Scholar
  74. 74.
    Tsai YH, Wang CH, Hsueh PR, Jean SS, Chen FL, Lee WS. Breakthrough invasive Trichosporon asahii infection in an uremic patient with systemic calciphylaxis complicating necrotizing fasciitis during echinocandin therapy for C. tropicalis. J Microbiol Immunol Infect. 2019. Scholar
  75. 75.
    Sato E, Togawa A, Masaki M, Shirahashi A, Kumagawa M, Kawano Y, et al. Community-acquired Disseminated Exophiala dermatitidis Mycosis with Necrotizing Fasciitis in Chronic Graft-versus-host Disease. Internal Medicine. 2019;advpub.
  76. 76.
    Pushker N, Chra M, Bajaj MS, Ghose S, Naik N, Kashyap S, et al. Necrotizing periorbital Fusarium infection--an emerging pathogen in immunocompetent individuals. J Infect. 2002;44(4):236–9. Scholar
  77. 77.
    Walsh TJ, Gamaletsou MN, McGinnis MR, Hayden RT, Kontoyiannis DP. Early clinical and laboratory diagnosis of invasive pulmonary, extrapulmonary, and disseminated mucormycosis (zygomycosis). Clin Infect Dis. 2012;54(Suppl 1):S55–60. Scholar
  78. 78.
    Ambrosioni J, Bouchuiguir-Wafa K, Garbino J. Emerging invasive zygomycosis in a tertiary care center: epidemiology and associated risk factors. Int J Infect Dis. 2010;14(Suppl 3):e100–3. Scholar
  79. 79.
    Verweij PE, Brandt ME. Aspergillus, Fusarium, and Other Opportunistic Moniliaceous Fungi. In: Murray PR, Baron EJ, editors. Manual of clinical microbiology. Washington, D.C.: ASM Press; 2007.Google Scholar
  80. 80.
    Cruciani M, Mengoli C, Loeffler J, Donnelly P, Barnes R, Jones BL, et al. Polymerase chain reaction blood tests for the diagnosis of invasive aspergillosis in immunocompromised people. Cochrane Database Syst Rev. 2015;9:Cd009551. Scholar
  81. 81.
    • Perfect JR, Dismukes WE, Dromer F, Goldman DL, Graybill JR, Hamill RJ, et al. Clinical practice guidelines for the management of cryptococcal disease: 2010 update by the infectious diseases society of america. Clin Infect Dis. 2010;50(3):291–322. most recent IDSA practice guidelines for the treatment of Cryptococcal disease with treatment implications for patients with cutaneous infection due to these organisms. CrossRefPubMedPubMedCentralGoogle Scholar
  82. 82.
    • Cornely OA, Arikan-Akdagli S, Dannaoui E, Groll AH, Lagrou K, Chakrabarti A, et al. ESCMID and ECMM joint clinical guidelines for the diagnosis and management of mucormycosis 2013. Clinical Microbiology and Infection. 2014;20:5–26. most recent ESCMID and ECMM practice guidelines for the management of mucromycosis with treatment guidance for cutaneous disease. CrossRefPubMedGoogle Scholar
  83. 83.
    • Tissot F, Agrawal S, Pagano L, Petrikkos G, Groll AH, Skiada A, et al. ECIL-6 guidelines for the treatment of invasive candidiasis, aspergillosis and mucormycosis in leukemia and hematopoietic stem cell transplant patients. Haematologica. 2017;102(3):433–44. most recent ECIL-6 practice guidelines for invasive fungal infections within patients with leukemia and HSCT with treatment guidance for cutaneous disease. CrossRefPubMedPubMedCentralGoogle Scholar
  84. 84.
    • Stevens DL, Bisno AL, Chambers HF, Dellinger EP, Goldstein EJC, Gorbach SL, et al. Executive Summary: Practice Guidelines for the Diagnosis and Management of Skin and Soft Tissue Infections: 2014 Update by the Infectious Diseases Society of America. Clinical Infectious Diseases. 2014;59(2):147–59. most recent IDSA practice guidelines for the management of soft tissue infections with a review and management recommendations of fungal soft tissue infections in general. CrossRefPubMedGoogle Scholar
  85. 85.
    Espinel-Ingroff A, Chakrabarti A, Chowdhary A, Cordoba S, Dannaoui E, Dufresne P, et al. Multicenter Evaluation of MIC Distributions for Epidemiologic Cutoff Value Definition To Detect Amphotericin B, Posaconazole, and Itraconazole Resistance among the Most Clinically Relevant Species of Mucorales. Antimicrob Agents Chemother. 2015;59(3):1745–50. Scholar
  86. 86.
    Caramalho R, Maurer E, Binder U, Araújo R, Dolatabadi S, Lass-Flörl C, et al. Etest cannot be recommended for in vitro susceptibility testing of mucorales. Antimicrob Agents Chemother. 2015;59(6):3663–5. Scholar
  87. 87.
    Brugiere O, Dauriat G, Mal H, Marrash-Chalha R, Fournier M, Groussard O, et al. Pulmonary mucormycosis (zygomycosis) in a lung transplant recipient: recovery after posaconazole therapy. Transplantation. 2005;80(9):1361–2. Scholar
  88. 88.
    Garbino J, Uçkay I, Amini K, Puppo M, Richter M, Lew D. <em>Absidia</em> posttraumatic infection: successful treatment with posaconazole. Journal of Infection. 2005;51(3):e135–e8. Scholar
  89. 89.
    van Burik JA, Hare RS, Solomon HF, Corrado ML, Kontoyiannis DP. Posaconazole is effective as salvage therapy in zygomycosis: a retrospective summary of 91 cases. Clin Infect Dis. 2006;42(7):e61–5. Scholar
  90. 90.
    Dolton MJ, Ray JE, Chen SC, Ng K, Pont L, McLachlan AJ. Multicenter study of posaconazole therapeutic drug monitoring: exposure-response relationship and factors affecting concentration. Antimicrob Agents Chemother. 2012;56(11):5503–10. Scholar
  91. 91.
    Krishna G, Ma L, Martinho M, Preston RA, O'Mara E. A new solid oral tablet formulation of posaconazole: a randomized clinical trial to investigate rising single- and multiple-dose pharmacokinetics and safety in healthy volunteers. J Antimicrob Chemother. 2012;67(11):2725–30. Scholar
  92. 92.
    Marty FM, Ostrosky-Zeichner L, Cornely OA, Mullane KM, Perfect JR, Thompson GR 3rd, et al. Isavuconazole treatment for mucormycosis: a single-arm open-label trial and case-control analysis. Lancet Infect Dis. 2016;16(7):828–37. Scholar
  93. 93.
    Reed C, Bryant R, Ibrahim AS, Edwards J Jr, Filler SG, Goldberg R, et al. Combination polyene-caspofungin treatment of rhino-orbital-cerebral mucormycosis. Clin Infect Dis. 2008;47(3):364–71. Scholar
  94. 94.
    Kyvernitakis A, Torres HA, Jiang Y, Chamilos G, Lewis RE, Kontoyiannis DP. Initial use of combination treatment does not impact survival of 106 patients with haematologic malignancies and mucormycosis: a propensity score analysis. Clinical Microbiology and Infection. 2016;22(9):811.e1–8. Scholar
  95. 95.
    Pagano L, Cornely OA, Busca A, Caira M, Cesaro S, Gasbarrino C, et al. Combined antifungal approach for the treatment of invasive mucormycosis in patients with hematologic diseases: a report from the SEIFEM and FUNGISCOPE registries. Haematologica. 2013;98(10):e127–e30. Scholar
  96. 96.
    Herbrecht R, Denning DW, Patterson TF, Bennett JE, Greene RE, Oestmann JW, et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med. 2002;347(6):408–15. Scholar
  97. 97.
    Walsh TJ, Raad I, Patterson TF, Chandrasekar P, Donowitz GR, Graybill R, et al. Treatment of invasive aspergillosis with posaconazole in patients who are refractory to or intolerant of conventional therapy: an externally controlled trial. Clin Infect Dis. 2007;44(1):2–12. Scholar
  98. 98.
    Maertens JA, Raad II, Marr KA, Patterson TF, Kontoyiannis DP, Cornely OA, et al. Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by Aspergillus and other filamentous fungi (SECURE): a phase 3, randomised-controlled, non-inferiority trial. Lancet. 2016;387(10020):760–9. Scholar
  99. 99.
    Marr KA, Schlamm HT, Herbrecht R, Rottinghaus ST, Bow EJ, Cornely OA, et al. Combination antifungal therapy for invasive aspergillosis: a randomized trial. Ann Intern Med. 2015;162(2):81–9. Scholar
  100. 100.
    Marr KA, Boeckh M, Carter RA, Kim HW, Corey L. Combination antifungal therapy for invasive aspergillosis. Clin Infect Dis. 2004;39(6):797–802. Scholar
  101. 101.
    Upton A, Kirby KA, Carpenter P, Boeckh M, Marr KA. Invasive aspergillosis following hematopoietic cell transplantation: outcomes and prognostic factors associated with mortality. Clin Infect Dis. 2007;44(4):531–40. Scholar
  102. 102.
    Cohen-Ludmann C, Kerob D, Feuilhade M, Chaine B, Guermazi A, Janier M, et al. Zygomycosis of the Penis Due to Rhizopus oryzae Successfully Treated With Surgical Debridement and a Combination of High-Dose Liposomal and Topical Amphotericin B. JAMA Dermatology. 2006;142(12):1650–66. Scholar
  103. 103.
    Di Pentima MC, Chan S, Powell J, Napoli JA, Walter AW, Walsh TJ. Topical amphotericin B in combination with standard therapy for severe necrotizing skin and soft-tissue mucormycosis in an infant with bilineal leukemia: case report and review. J Pediatr Hematol Oncol. 2014;36(7):e468–70. Scholar
  104. 104.
    Rodriguez CJ, Tribble DR, Malone DL, Murray CK, Jessie EM, Khan M, et al. Treatment of Suspected Invasive Fungal Infection in War Wounds. Military Medicine. 2018;183(suppl_2):142–6. Scholar
  105. 105.
    Spellberg B, Ibrahim AS, Chin-Hong PV, Kontoyiannis DP, Morris MI, Perfect JR, et al. The Deferasirox-AmBisome Therapy for Mucormycosis (DEFEAT Mucor) study: a randomized, double-blinded, placebo-controlled trial. J Antimicrob Chemother. 2012;67(3):715–22. Scholar
  106. 106.
    John BV, Chamilos G, Kontoyiannis DP. Hyperbaric oxygen as an adjunctive treatment for zygomycosis. Clin Microbiol Infect. 2005;11(7):515–7. Scholar
  107. 107.
    Tragiannidis A, Groll AH. Hyperbaric oxygen therapy and other adjunctive treatments for zygomycosis. Clin Microbiol Infect. 2009;15(Suppl 5):82–6. Scholar
  108. 108.
    Abzug MJ, Walsh TJ. Interferon-gamma and colony-stimulating factors as adjuvant therapy for refractory fungal infections in children. Pediatr Infect Dis J. 2004;23(8):769–73.CrossRefGoogle Scholar
  109. 109.
    Gil-Lamaignere C, Simitsopoulou M, Roilides E, Maloukou A, Winn RM, Walsh TJ. Interferon- gamma and granulocyte-macrophage colony-stimulating factor augment the activity of polymorphonuclear leukocytes against medically important zygomycetes. J Infect Dis. 2005;191(7):1180–7. Scholar
  110. 110.
    Hubel K, Dale DC, Engert A, Liles WC. Current status of granulocyte (neutrophil) transfusion therapy for infectious diseases. J Infect Dis. 2001;183(2):321–8. Scholar
  111. 111.
    Chamilos G, Lewis RE, Kontoyiannis DP. Lovastatin has significant activity against zygomycetes and interacts synergistically with voriconazole. Antimicrob Agents Chemother. 2006;50(1):96–103. Scholar
  112. 112.
    Bellanger AP, Tatara AM, Shirazi F, Gebremariam T, Albert ND, Lewis RE, et al. Statin Concentrations Below the Minimum Inhibitory Concentration Attenuate the Virulence of Rhizopus oryzae. J Infect Dis. 2016;214(1):114–21. Scholar
  113. 113.
    Grimaldi D, Pradier O, Hotchkiss RS, Vincent JL. Nivolumab plus interferon-gamma in the treatment of intractable mucormycosis. Lancet Infect Dis. 2017;17(1):18. Scholar
  114. 114.
    Parks T, Wilson C, Curtis N, Norrby-Teglund A, Sriskandan S. Polyspecific Intravenous Immunoglobulin in Clindamycin-treated Patients With Streptococcal Toxic Shock Syndrome: A Systematic Review and Meta-analysis. Clin Infect Dis. 2018;67(9):1434–6. Scholar
  115. 115.
    Madsen MB, Hjortrup PB, Hansen MB, Lange T, Norrby-Teglund A, Hyldegaard O, et al. Immunoglobulin G for patients with necrotising soft tissue infection (INSTINCT): a randomised, blinded, placebo-controlled trial. Intensive Care Med. 2017;43(11):1585–93. Scholar
  116. 116.
    Kadri SS, Swihart BJ, Bonne SL, Hohmann SF, Hennessy LV, Louras P, et al. Impact of Intravenous Immunoglobulin on Survival in Necrotizing Fasciitis With Vasopressor-Dependent Shock: A Propensity Score-Matched Analysis From 130 US Hospitals. Clin Infect Dis. 2017;64(7):877–85. Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2019

Authors and Affiliations

  1. 1.Department of Medicine, Division of Infectious DiseasesColumbia University Irving Medical CenterNew YorkUSA

Personalised recommendations